# Staccato Loxapine Pulmonary Safety in Patients With COPD

> **NCT00889837** · PHASE1 · COMPLETED · sponsor: **Alexza Pharmaceuticals, Inc.** · enrollment: 53 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** Inhaled Loxapine
- **DRUG:** Inhaled Placebo

## Key facts

- **NCT ID:** NCT00889837
- **Lead sponsor:** Alexza Pharmaceuticals, Inc.
- **Sponsor class:** UNKNOWN
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2017-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00889837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00889837, "Staccato Loxapine Pulmonary Safety in Patients With COPD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00889837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*